| | |
| Clinical data | |
|---|---|
| Other names | PF-00251802; PF-251802 |
| Drug class | Selective glucocorticoid receptor modulator |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C29H29F3N2O2 |
| Molar mass | 494.558 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Dagrocorat (developmental code names PF-00251802, PF-251802) is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM) which was under development for the treatment of rheumatoid arthritis but was never marketed. [1] [2] [3] [4] It is described as a partial agonist and "dissociable" agonist of the glucocorticoid receptor. [5] [6] The drug reached phase I clinical trials prior to the discontinuation of its development. [1] [3] [4] The C2α dihydrogen phosphate ester of dagrocorat, fosdagrocorat, was also under investigation, but its development was terminated as well. [7]